Accelerate Your Path to the Clinic With VeriSIM Life’s Predictive Translational AI Platform
This January, VeriSIM Life’s CEO Dr. Jo Varshney and the leadership team will be in San Francisco for the JPM Healthcare Conference and BIO One-on-One Partnering. They will be meeting with innovators, investors, and development teams looking to modernize how therapies move from concept to clinic.
Why Meet With the CEO and Team?
The industry is shifting fast toward human-relevant, non-animal evidence and computational design — areas where VeriSIM Life has built deep validation across dozens of diseases.
At JPM, the CEO and team will introduce how BIOiSIM® not only predicts translational outcomes but also generates new, viable drug candidates by designing molecules that fit biological reality from the start, not just chemical rules.
BIOiSIM enables teams to:
- Generate novel molecules optimized for exposure, safety, and human biology
- Prioritize new chemical matter based on modeled clinical viability
- Reduce animal studies through mechanistic, explainable AI via virtual testing
- Understand toxicity, organ effects, and translational risk earlier
- Build strong IND-ready packages with explainable, human-relevant modeling
- Accelerate timelines without sacrificing confidence or scientific rigor
This is discovery and development reimagined: molecules created with translational success built in from day one.
Who Should Connect
Teams looking to:
- Discover or design novel molecules with higher likelihood of clinical success
- Strengthen preclinical packages with model-driven, AI/mechanistic evidence
- Improve the prediction of human biology before costly studies
- Optimize formulations, delivery strategies, or dosing
- Explore integrated co-development or platform partnerships
Where to Meet
JPM Healthcare Conference – San Francisco
BIO One-on-One Partnering – Available Throughout JPM Week
Secure Time With the CEO and VeriSIM Life Team
JPM Week fills quickly. Reserve time early to explore how VeriSIM Life can help you design, evaluate, and advance novel molecules with far greater certainty — and move programs to patients faster.